Navigation Links
KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet

ST. LOUIS, Dec. 2 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company ( KVa/KVb) today announced that that it has entered into an employment agreement with Interim President and Chief Executive Officer David A. Van Vliet with a term through December 31, 2011. Mr. Van Vliet has served as Interim President and Chief Executive Officer since December 2008.

The employment agreement provides continuity of senior leadership as the Company seeks to resume the manufacture and distribution of products marketed by its subsidiaries, ETHEX and Ther-Rx, in accordance with its consent decree with the U.S. Food and Drug Administration (FDA).

"This agreement reflects the tremendous job David has done leading KV during a very challenging and critical period and ensures continuity of his effective stewardship as we execute against our consent decree and seek to return to market," said Terry Hatfield, Chairman of KV Pharmaceutical.

"While we still have work to do to achieve success, we are making the kind of progress that has our organization believing we can reach our goals," said Mr. Van Vliet. "Our emphasis on building a culture of compliance, openness, teamwork, and innovation is being embraced and is having a meaningful impact."

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company's branded drug subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate Web site at

SOURCE KV Pharmaceutical Company

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends
2. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
3. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
4. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
5. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
6. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
7. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
8. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
9. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
10. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
11. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... today announced that Chief Executive Officer Antonius Schuh, Ph.D., ... 27 th Annual Piper Jaffray Healthcare Conference. ... the New York Palace Hotel in New ... 1:30 p.m. EST. Mr. Schuh will be available for ...
(Date:11/25/2015)... International plc (NASDAQ: ENDP ) (TSX: ENL) today announced ... discuss corporate updates at the 27 th Annual Piper ... on Wednesday, December 2, 2015 at 1 p.m. ET. ... the link to the event. Participants should allow approximately 10 ... site and download any streaming media software needed to listen ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (the "New Investors"), pursuant to which BioLight and the ... BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private placement. ... commercialization of its innovative IOPtimate™ system used in the ... regulatory approval pathway process for the IOPtimate™ system with ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... been recognized once again for its stellar workplace culture with the company’s Cincinnati ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business ...
(Date:11/25/2015)... NV (PRWEB) , ... November 25, 2015 , ... Dr. ... patients to learn more about hair loss treatment with the Capillus272™ Pro laser therapy ... effective solution for thicker and fuller hair, without the need for surgery, prescription pills, ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
Breaking Medicine News(10 mins):